Cargando…

Neuroendocrine Carcinomas of the Digestive Tract: What Is New?

SIMPLE SUMMARY: In this narrative review, we describe the current data and management of neuroendocrine carcinomas (NEC) of the digestive tract. These tumors are very rare and suffer from a lack of clinical trials which would allow for standardized therapeutic management. To date, most guidelines co...

Descripción completa

Detalles Bibliográficos
Autores principales: Pellat, Anna, Cottereau, Anne Ségolène, Terris, Benoit, Coriat, Romain
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8345167/
https://www.ncbi.nlm.nih.gov/pubmed/34359666
http://dx.doi.org/10.3390/cancers13153766
_version_ 1783734565047631872
author Pellat, Anna
Cottereau, Anne Ségolène
Terris, Benoit
Coriat, Romain
author_facet Pellat, Anna
Cottereau, Anne Ségolène
Terris, Benoit
Coriat, Romain
author_sort Pellat, Anna
collection PubMed
description SIMPLE SUMMARY: In this narrative review, we describe the current data and management of neuroendocrine carcinomas (NEC) of the digestive tract. These tumors are very rare and suffer from a lack of clinical trials which would allow for standardized therapeutic management. To date, most guidelines come from studies in small-cell lung cancer, which is a similar entity in the lung. The incidence of NEC is rising and their prognostic is very low, underlying the urgent need for more trials to help define their best management. ABSTRACT: Neuroendocrine carcinomas (NEC) are rare tumors with a rising incidence. They show poorly differentiated morphology with a high proliferation rate (Ki-67 index). They frequently arise in the lung (small and large-cell lung cancer) but rarely from the gastrointestinal tract. Due to their rarity, very little is known about digestive NEC and few studies have been conducted. Therefore, most of therapeutic recommendations are issued from work on small-cell lung cancers (SCLC). Recent improvement in pathology and imaging has allowed for better detection and classification of high-grade NEN. The 2019 World Health Organization (WHO) classification has described a new entity of well-differentiated grade 3 neuroendocrine tumors (NET G-3), with better prognosis, that should be managed separately from NEC. NEC are aggressive neoplasms often diagnosed at a metastatic state. In the localized setting, surgery can be performed in selected patients followed by adjuvant platinum-based chemotherapy. Concurrent chemoradiotherapy is also an option for NEC of the lung, rectum, and esophagus. In metastatic NEC, chemotherapy is administered with a classic combination of platinum salts and etoposide in the first-line setting. Peptide receptor radionuclide therapy (PRRT) has shown positive results in high-grade NEN populations and immunotherapy trials are still ongoing. Available therapies have improved the overall survival of NEC but there is still an urgent need for improvement. This narrative review sums up the current data on digestive NEC while exploring future directions for their management.
format Online
Article
Text
id pubmed-8345167
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-83451672021-08-07 Neuroendocrine Carcinomas of the Digestive Tract: What Is New? Pellat, Anna Cottereau, Anne Ségolène Terris, Benoit Coriat, Romain Cancers (Basel) Review SIMPLE SUMMARY: In this narrative review, we describe the current data and management of neuroendocrine carcinomas (NEC) of the digestive tract. These tumors are very rare and suffer from a lack of clinical trials which would allow for standardized therapeutic management. To date, most guidelines come from studies in small-cell lung cancer, which is a similar entity in the lung. The incidence of NEC is rising and their prognostic is very low, underlying the urgent need for more trials to help define their best management. ABSTRACT: Neuroendocrine carcinomas (NEC) are rare tumors with a rising incidence. They show poorly differentiated morphology with a high proliferation rate (Ki-67 index). They frequently arise in the lung (small and large-cell lung cancer) but rarely from the gastrointestinal tract. Due to their rarity, very little is known about digestive NEC and few studies have been conducted. Therefore, most of therapeutic recommendations are issued from work on small-cell lung cancers (SCLC). Recent improvement in pathology and imaging has allowed for better detection and classification of high-grade NEN. The 2019 World Health Organization (WHO) classification has described a new entity of well-differentiated grade 3 neuroendocrine tumors (NET G-3), with better prognosis, that should be managed separately from NEC. NEC are aggressive neoplasms often diagnosed at a metastatic state. In the localized setting, surgery can be performed in selected patients followed by adjuvant platinum-based chemotherapy. Concurrent chemoradiotherapy is also an option for NEC of the lung, rectum, and esophagus. In metastatic NEC, chemotherapy is administered with a classic combination of platinum salts and etoposide in the first-line setting. Peptide receptor radionuclide therapy (PRRT) has shown positive results in high-grade NEN populations and immunotherapy trials are still ongoing. Available therapies have improved the overall survival of NEC but there is still an urgent need for improvement. This narrative review sums up the current data on digestive NEC while exploring future directions for their management. MDPI 2021-07-27 /pmc/articles/PMC8345167/ /pubmed/34359666 http://dx.doi.org/10.3390/cancers13153766 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Pellat, Anna
Cottereau, Anne Ségolène
Terris, Benoit
Coriat, Romain
Neuroendocrine Carcinomas of the Digestive Tract: What Is New?
title Neuroendocrine Carcinomas of the Digestive Tract: What Is New?
title_full Neuroendocrine Carcinomas of the Digestive Tract: What Is New?
title_fullStr Neuroendocrine Carcinomas of the Digestive Tract: What Is New?
title_full_unstemmed Neuroendocrine Carcinomas of the Digestive Tract: What Is New?
title_short Neuroendocrine Carcinomas of the Digestive Tract: What Is New?
title_sort neuroendocrine carcinomas of the digestive tract: what is new?
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8345167/
https://www.ncbi.nlm.nih.gov/pubmed/34359666
http://dx.doi.org/10.3390/cancers13153766
work_keys_str_mv AT pellatanna neuroendocrinecarcinomasofthedigestivetractwhatisnew
AT cottereauannesegolene neuroendocrinecarcinomasofthedigestivetractwhatisnew
AT terrisbenoit neuroendocrinecarcinomasofthedigestivetractwhatisnew
AT coriatromain neuroendocrinecarcinomasofthedigestivetractwhatisnew